Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19
15/07/2021 18:41
July 15 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3
CLINICAL
TRIAL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - PHASE 3 CLINICAL TRIAL ONGOING
WITH
NEXT DSMB MEETING AT 600 COMPLETED PATIENTS
* REVIVE THERAPEUTICS LTD - AIM TO COMPLETE ENROLLMENT IN
Q3-2021
AND FDA EUA SUBMISSION IN LATE-Q3/Q4-2021.
* REVIVE THERAPEUTICS LTD - CURRENTLY AT 41 CLINICAL SITES
AND TO
ENGAGE A MINIMUM OF 50 CLINICAL SITES
Source text for Eikon: ID:nGNX6R7f7r
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure